CHEMOTHERAPY APR. 1982
|
|
- きよたつ しろみず
- 5 years ago
- Views:
Transcription
1
2 VOL.30 S-1 CHEMOTHERAPY Table 1 Dose of CTT and subjects i. v.: Intravenous bolus injection d. i. v.: Intravenous drip infusion i. m.: Intramuscular injection Fig. 1 Schedule for examination of CTT, 1.0g ~5 i. v. Only GOT, GPT, Al- P and blood glucose were examined
3 Table 2 Test item Fig. 2 Chemical structure of CTT and its tautomer (1) Clinical symptoms. Subjective, Objective, Allergy, Others (2) Blood pressure (3) Electrocardiogram (4) Body temperature (5) Hematology : WBC, RBC, Hb, Ht, Platelet, WBC differential count (6) Blood chemistry : Total protein, A/G ratio, GOT, GPT, Al-P, LAP, ƒá-gtp, LDH, Total cholesterol, Blood sugar, BUN, Creatinine, Na, K (7) COOMBS' test : Direct, Indirect (8) Urinalysis : Sugar, Acetone, Protein, (9) Plasma level of CTT (10) Urinary level of CTT Bilirubin, Occult blood, Urobilinogen, Sediments Table 3 Measurement by high performance liquid chromatography (HPLC) HPLC conditions Column : Nucleosil Cl 8(5ƒÊm), Column temp. 150mm ~4mm i. d. Mobile phase : 8% Acetonitrile- 92% 0.1 M Sodium dihydrogen phosphate (ph 3.0) Pressure : 2,000 psi Flow : 1.2ml/ min Detector : UV (280nm) Chart speed : 5mm/ min
4 VOL.30 S-1 CHEMOTHERAPY Fig. 3 Plasma level of CTT Fig. 4 Plasma level of CTT Table 4-1 Plasma level of CTT, A single dose, i. v. (Group 1, 3) Mean }S. E. Đg/ml Table 4-2 Plasma level of CTT, Multidose, i. v. (Group 2, 4) Mean }S. E. Đg/ml
5 Table 4-3 Plasma level of CTT, Multidose, iv. (Group 7, 8) (1) Group 7: 1.0g ~5 i. v.(n= 3) Mean }S. E.ƒÊg/ ml, n. d.: Not detectable (2) Group 8: 1.0g ~11 i. v.(n= 4) Mean }S. E.ƒÊg/ ml Table 4-4 Plasma level of CTT, A single dose, d. i. v.(group 5, 6) Mean }S.E.ƒÊg/ ml, n. d.: Not detectable Table 4-5 Plasma level of MT, A single dose, i. m.(group 9) Mean }S. E.ƒÊg/ ml
6 VOL.30 S-1 CHEMOTHERAPY Table 5 Pharmacokinetic parameters of CTT
7 Fig. 5 Plasma level of CTT, Multidose, 1.0g ~5 i. v. Fig. 6 Plasma level of CII, Multidose, 1.0g ~11 i. v.
8 VOL.30 S-1 CHEMOTHERAPY Fig. 7 Urinary excretion of CTT Table 6-1 Urinary excretion of CU, A single dose, i. v.(group 1, 3) Mean }S. E.
9 Table 6-2 Urinary excretion of CTT, Multidose, i. v.(group 2, 4) Mean }S. E. Table 6-3 Urinary excretion of CTT, Multidose, i. v.(group 7, 8) (1) Group 7: 1.0g ~5 i. v.(n= 3) Mean }S. E. a) Rec. : Recovery (%) Cum. rec. : Cumulative recovery (%) b) Concn.(ƒÊg/ml) : Concentration (ƒêg/ml)
10 VOL.30 S-1 CHEMOTHERAPY (2) Group 8: 1.0g ~11 i. v.(n= 4) Mean }S. E. a) Rec. : Recovery (%) Cum. rec. : Cumulative recovery (%) b) Concn. (Đg/ml) : Concentration (Đg/ml) Table 6-4 Urinary excretion of CTT, A single dose, d. i. v.(group 5, 6) Mean }S. E. Table 6-5 Urinary excretion of CTT, A single dose, i. m.(group 9) Mean }S. E.
11 Table 7 Urinary recovery of CTT and its tautomer
12 VOL.30 S-1 1) TACHIBANA, A.; M. KOMIYA, Y. KIKUCHI, K. YANO& K. MASHIMO Pharmacological studies on YM09330, a new parenteral cephamycin derivative. 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. Abstr. No. 563, ) YANO, K.; K. SUZAKI, M. SAITO, M. TODA, T. SAITO& S. MITSUHASHI: In vitro and in vivo antibacterial activities of YM09330, a new cephamycin derivative. ibid. Abstr. No. 564, 1979
13 PHASE- I CLINICAL STUDY ON CEFOTETAN (YM09330) MASARU KOYAMA and KEIICHI NAKAGAWA Department of Internal Medicine, Tokyo Kyosai Hospital MASAYUKI KOMIYA, YASUHIRO KIKUCHI, AKIO TACHIBANA and KUNIICHIRO YANO Central Research Laboratories, Yamanouchi Pharmaceutical Co., Ltd. Cefotetan (CTT, YM09330), a new parenteral cephamycin antibiotic, was administered to 28 healthy male volunteers to study its safety and pharmacokinetics. Doses of cefotetan were I) single intravenous bolus injection (i. v.), of 0.5 g II) 0.5 g i.v. twice a day for one day III) single 1.0 g i. v. IV) 1.0 g i. v. twice a day for one day V) single intravenous drip infusion (d. i. v.) of 2.0 g VI) single 3.0 g d. i. v. VII) VIII) 1.0 g i.v. twice a day for 2.5 days 1.0 g i.v. twice a day for 5.5 days IX) single intramuscular injection (i. m.) of 0.5 g Results were as follows; 1) No abnormalities attributable to cefotetan were noted in any examined items such as symptoms, blood pressure, heart rate, electrocardiogram, body temperature, hematology, blood chemistry, COOMBS' test and urinalysis. 2) The mean plasma levels of cefotetan 15 min after dosing were 85.2 and 171 /2g/ml for 0.5 g i. v. and 1.0 g i. v. respectively. And they were slowly declined to 7.6 and 17.4 Đg/ml at 8 h after dosing. The average were calculated to be 3.11 h and 3.40 h for 0.5 g i.v. and1.0 g i. v. respectively by the two compartment open model. Plasma levels of cefotetan were not accumulated even when cefotetan was intravenously administered with 11 consecutive doses of I g at intervals of 12 h. 3) Seventy- five `eighty-five% of cefotetan were excreted in 24 h urine after dosing, and approximately 5% of cefotetan were found in the form of the tautomer. No metabolites of cefotetan were detected in urine.
CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Fig. 2 Comparison of standard curves of CTT on various test organisms by cylinder plate method Column
More informationCHEMOTHERAPY SEPT. 1991
CHEMOTHERAPY SEPT. 1991 VOL. 39 S-3 Table 1. Background of characteristics and allocation of 9 healthy male volunteers in a single-dose study on betamipron Table 2. Background of characteristics and allocation
More informationVOL.39 S-3
VOL.39 S-3 CHEMOTHERAPY SEPT.1991 Table 1. Background of characteristics and allocation of 5 healthy male volunteers in a multiple-dose study on panipenem/betamipron Day 1 Fig. 1. Schedule of multiple-dose
More informationCHEMO THER APY Table 1. Background of the volunteers in the phase I clinical trial of ME1207 Table 2. Methods for Phase I clinical trial of ME1207 All doses are expressed in terms of potency as ME1206
More informationCHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57) VOL.30 S-1 CHEMOTHERAPY Table 1 Method of HPLC-assay of CTT and its
More information日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
More informationVOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
More informationCHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
More informationVOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains
CHEMOTHERAPY APR. 1982 Fig. 1 Chemical structure of cefotetan (CTT, YM09330) VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT
More informationFig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
More informationFig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal
More informationCHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
More informationJan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Jan. 1987 Jan. 1987 THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis
More informationCHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
More informationCHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
More informationCHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
More informationTable 1. Healthy volunteers of the studies on NM441 Table 2. Examination items 1. Symptoms 2. Blood pressure, Pulse rate, Respiratory rate 1), Body temperature, Body weight, ECG 3. Labolatory test 1) Hematology:
More informationCHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
More informationFig. 1 Chemical structure of KW-1070
Fig. 1 Chemical structure of KW-1070 Fig. 2 Sensitivity distribution of clinical isolates Fig. 4 Sensitivity distribution of clinical isolates Fig. 3 Sensitivity distribution of clinical isolates Fig.
More informationCHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
More informationTable 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
More information平成18年版 男女共同参画白書
i ii iii iv v vi vii viii ix 3 4 5 6 7 8 9 Column 10 11 12 13 14 15 Column 16 17 18 19 20 21 22 23 24 25 26 Column 27 28 29 30 Column 31 32 33 34 35 36 Column 37 Column 38 39 40 Column 41 42 43 44 45
More informationVOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
More informationCHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
More informationCHEMOTHERAPY MAY 1988
VOL. 36 NO. 5 Table 1. Subjects studied B. W. Body weight B. H. Body height Abbreviations Ccr Endogenous creatinine clearance PSP Phenolsulfonphthalein test for 15 min BUN Blood urea nitrogen Scr Serum
More informationCHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation
CHEMOTHERAPY CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation CHEMOTHERAPY Table 1 Preliminaly test of AM- 715 1): Mean } SD *: Significant difference
More informationFig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
More informationVOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
More informationVOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
More informationKey words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.
Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S. Table 1. Clinical summary of acute uncomplicated cystitis patients treated with 7432-S UTI : Criteria by the
More informationCHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
More informationVol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2
Vol. 36, Special Issue, S 3 S 18 (2015) PK Phase I Introduction to Pharmacokinetic Analysis Focus on Phase I Study 1 2 Kazuro Ikawa 1 and Jun Tanaka 2 1 2 1 Department of Clinical Pharmacotherapy, Hiroshima
More informationDec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)
Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45) 2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47) 2308(48) THE JAPANESE
More informationSC-85X2取説
I II III IV V VI .................. VII VIII IX X 1-1 1-2 1-3 1-4 ( ) 1-5 1-6 2-1 2-2 3-1 3-2 3-3 8 3-4 3-5 3-6 3-7 ) ) - - 3-8 3-9 4-1 4-2 4-3 4-4 4-5 4-6 5-1 5-2 5-3 5-4 5-5 5-6 5-7 5-8 5-9 5-10 5-11
More information<4D6963726F736F667420506F776572506F696E74202D208376838C835B83938365815B835683878393312E707074205B8CDD8AB78382815B83685D>
i i vi ii iii iv v vi vii viii ix 2 3 4 5 6 7 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
More informationCHEMOTHERAPY JUNE 1988 ( })-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-l-piperaziny1) 4-oxo-3-quinolinecarboxylic acid hydrochloride Fig. 1. Chemica
CHEMOTHERAPY JUNE 1988 ( })-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-l-piperaziny1) 4-oxo-3-quinolinecarboxylic acid hydrochloride Fig. 1. Chemical structure of NY-198 VOL. 36 5-2 CHEMOTHERAPY Mouse
More information988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
More informationCHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
More informationCHEMOTHERAPY APR. 1984
VOL.32 S-3 CHEMOTHERAPY dihydro-4-oxo-7-(1-piperazinyl)-1, 8-naphthyridine- CHEMOTHERAPY APR. 1984 VOL.32 S-3 CHEMOTHERAPY Table 1 Implantation rates and post- implantation survival rates in females mated
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More informationCHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
More informationA Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc
A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, School of Medicine, Tokushima University, Tokushima Fetal
More information1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
More informationTable 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
More informationTable 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
More informationIII
III 1 1 2 1 2 3 1 3 4 1 3 1 4 1 3 2 4 1 3 3 6 1 4 6 1 4 1 6 1 4 2 8 1 4 3 9 1 5 10 1 5 1 10 1 5 2 12 1 5 3 12 1 5 4 13 1 6 15 2 1 18 2 1 1 18 2 1 2 19 2 2 20 2 3 22 2 3 1 22 2 3 2 24 2 4 25 2 4 1 25 2
More informationiii iv v vi vii viii ix 1 1-1 1-2 1-3 2 2-1 3 3-1 3-2 3-3 3-4 4 4-1 4-2 5 5-1 5-2 5-3 5-4 5-5 5-6 5-7 6 6-1 6-2 6-3 6-4 6-5 6 6-1 6-2 6-3 6-4 6-5 7 7-1 7-2 7-3 7-4 7-5 7-6 7-7 7-8 7-9 7-10 7-11 8 8-1
More informationTable 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
More informationこれわかWord2010_第1部_100710.indd
i 1 1 2 3 6 6 7 8 10 10 11 12 12 12 13 2 15 15 16 17 17 18 19 20 20 21 ii CONTENTS 25 26 26 28 28 29 30 30 31 32 35 35 35 36 37 40 42 44 44 45 46 49 50 50 51 iii 52 52 52 53 55 56 56 57 58 58 60 60 iv
More informationパワポカバー入稿用.indd
i 1 1 2 2 3 3 4 4 4 5 7 8 8 9 9 10 11 13 14 15 16 17 19 ii CONTENTS 2 21 21 22 25 26 32 37 38 39 39 41 41 43 43 43 44 45 46 47 47 49 52 54 56 56 iii 57 59 62 64 64 66 67 68 71 72 72 73 74 74 77 79 81 84
More informationこれでわかるAccess2010
i 1 1 1 2 2 2 3 4 4 5 6 7 7 9 10 11 12 13 14 15 17 ii CONTENTS 2 19 19 20 23 24 25 25 26 29 29 31 31 33 35 36 36 39 39 41 44 45 46 48 iii 50 50 52 54 55 57 57 59 61 63 64 66 66 67 70 70 73 74 74 77 77
More informationVOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
More informationuntitled
i ii iii iv v 43 43 vi 43 vii T+1 T+2 1 viii 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 a) ( ) b) ( ) 51
More informationFig. 1 Chemical structure of norfioxacin (AM-715)
Fig. 1 Chemical structure of norfioxacin (AM-715) Table 1 Serum and biliary concentration of norfloxacin (AM-715) Table 2 Protocol for clinical evaluation of norfloxacin (AM-715) in the treatment of biliary
More information2
1 2 3 4 5 6 7 8 9 10 I II III 11 IV 12 V 13 VI VII 14 VIII. 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 _ 33 _ 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 VII 51 52 53 54 55 56 57 58 59
More informationVOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
More informationTable 1.Distribution and number of cases with acute upper respiratory tract infections classified according to antimicrobial agents administered Table 2. Distribution of cases which were enrolled to set
More information報告書 H22-2A-09
061-0293 1757 TEL 0133-23-1211 2.0% 0.5% in vitro QOL Quality of Life 1 MCE-400 400 mpa s Duck Algin 350M M/G 0.8 70 80 C 20% 50 C 1.0% 5 C SV-10 5 C 10 ml E TV 20H model E 1 34 R24 1 ml 5 C 30 6 12 30
More informationPhysical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe
Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhei Kobayashi*2, Mamoru Nishimuta*2, Michiyuki Shimizu*3,
More informationVOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3
VOL. 20 NO. 5 CHEMOTHERAPY 653 2-Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3376, SDM, SIZ and SMZ against Gram-positive and negative
More information2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1
2108 CHEMOTHERAPY SEPT. 1977 Table 1 Antimicrobial spectrum Fig. 1 VOL. 25 NO. 7 CHEM 014 HERAPY 2109 Table 2 Susceptibility distribution of Staphylococcus aureus to aminoglycosides (54 strains) Table
More informationCHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
More informationCHEMOTHERAPY MAY. 1988
CHEMOTHERAPY MAY. 1988 CHEMOTHERAPY Fig. 1 Chemical structure CHEMOTHERAPY MAY. 1988 VOL.36 5-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY CHEMOTHERAPY MAY. 1988 VOL.36 S-1 CHEMOTHERAPY
More informationVOL. 36 S-3 CHEMOTHERAPY 239
238 CHEMOTHERAPY JULY 1988 Fig. 1 Chemical structure of 14C-TE-031 * : Labelled position VOL. 36 S-3 CHEMOTHERAPY 239 240 CHEMOTHERAPY JULY 1988 Table 1 Tissue levels of radioactivity in 12th and 19th
More informationepidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
More informationcoccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
More informationエクセルカバー入稿用.indd
i 1 1 2 3 5 5 6 7 7 8 9 9 10 11 11 11 12 2 13 13 14 15 15 16 17 17 ii CONTENTS 18 18 21 22 22 24 25 26 27 27 28 29 30 31 32 36 37 40 40 42 43 44 44 46 47 48 iii 48 50 51 52 54 55 59 61 62 64 65 66 67 68
More informationTazobactam Piperacillin Fig. 1. Plasma concentrations of tazobactam and piperacillin in animals following a single intravenous administration of tazobactam/piperacillin (10/40 mg/kg). Data represent the
More information01_.g.r..
I II III IV V VI VII VIII IX X XI I II III IV V I I I II II II I I YS-1 I YS-2 I YS-3 I YS-4 I YS-5 I YS-6 I YS-7 II II YS-1 II YS-2 II YS-3 II YS-4 II YS-5 II YS-6 II YS-7 III III YS-1 III YS-2
More informationVOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
More informationii iii iv CON T E N T S iii iv v Chapter1 Chapter2 Chapter 1 002 1.1 004 1.2 004 1.2.1 007 1.2.2 009 1.3 009 1.3.1 010 1.3.2 012 1.4 012 1.4.1 014 1.4.2 015 1.5 Chapter3 Chapter4 Chapter5 Chapter6 Chapter7
More informationCHEMOTHERAPY SEPT. 1970
CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY 691 692 CHEMOTHERAPY SEPT. 1970 VOL. 78 NO. CHEMOTHERAPY 5 写 真1 第1病 693 写 真4 日 In vitroの しCEZの 第22病
More information56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit
VOL.27 S-1 CHEMOTHERAPY 55 56 CHEMOTHERAPY JAN. 1979 Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit VOL.27 CHEMOT S-1 Fig. 2 Effect of Mezlocillin on blood pressure (Sensitivity
More informationVOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
More informationTitle 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): Issue Date URL
Title 外傷性脊髄損傷患者の泌尿器科学的研究第 3 報 : 上部尿路のレ線学的研究並びに腎機能について Author(s) 伊藤, 順勉 Citation 泌尿器科紀要 (1965), 11(4): 278-291 Issue Date 1965-04 URL http://hdl.handle.net/2433/112732 Right Type Departmental Bulletin Paper
More informationExperimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical Scho
Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical School While the problem of late pregnant hypertension
More information小児感染免疫第25巻第2号
Vol. 25No. 2145 1,2 1 1 1 1 2 2 2 TFLX 9 TFLX 450 mg16.6 mgkg TFLX 30 kg TFLX 2009 10 TFLX 1 1 2 3,4 TFLX 9 22 6 18 19 TFLX 450 mg150 mg 1 1 1 3 16.6 mgkg 20 20 0 21 3 135.0 cm0.1 S.D. 27.0 kg0.8 S.D.
More information活用ガイド (ソフトウェア編)
(Windows 95 ) ii iii iv NEC Corporation 1999 v P A R T 1 vi P A R T 2 vii P A R T 3 P A R T 4 viii P A R T 5 ix x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 6 5 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 4
More information8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio
7-14 2010 1 1 1 2 1 1 1 2 Fontaine II ASO61 3 API ASO ASO ASO API API KKKKKKKKKK ASO Fontaine II API Received April 14, 2009; Accepted July 16, 2009 I arteriosclerosis obliterans: ASO ASO 50 70 1,2 Fontaine
More informationTable1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
More information3 5 18 3 5000 1 2 7 8 120 1 9 1954 29 18 12 30 700 4km 1.5 100 50 6 13 5 99 93 34 17 2 2002 04 14 16 6000 12 57 60 1986 55 3 3 3 500 350 4 5 250 18 19 1590 1591 250 100 500 20 800 20 55 3 3 3 18 19 1590
More informationi ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13
More information困ったときのQ&A
ii iii iv NEC Corporation 1997 v P A R T 1 vi vii P A R T 2 viii P A R T 3 ix x xi 1P A R T 2 1 3 4 1 5 6 1 7 8 1 9 1 2 3 4 10 1 11 12 1 13 14 1 1 2 15 16 1 2 1 1 2 3 4 5 17 18 1 2 3 1 19 20 1 21 22 1
More information<95DB8C9288E397C389C88A E696E6462>
2011 Vol.60 No.4 p.332 338 Usefulness of regional education program for dietary salt reduction: Self-monitoring of urinary salt excretion Kenichiro YASUTAKE[1] Kayoko SAWANO[1] Shoko YAMAGUCHI[1] Hiroko
More informationCHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K
OCT. 1986 Fig. 1 Chemical structure of CVA-K VOL.34 S-4 heart infusion broth (Difco) 37.0 g, Resazurin 0.1% alcoholic solution (Wako) 1.0 ml, L-Cystein-HCl H2O (Wako) 0.5 g, Bact agar (Difco) 1.0 g, Deionized
More informationrectomy as the subjects of study, urinary steroid hormones were measured, and simultaneously the enzyme work and enzyme pattern related to the steroid metabolism, as proposed by Yoshida of our laboratory,
More information1) Chemical name: Fig. 1 Chemical structure of TE-031 (-)-(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2, PYranosyl)oxy]-14-ethyl-12,13-dihydroxy-7-meth 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexo- oxy-3,5,7,9,11,13-hexamethy1-6-[[3,4,6-trideoxy-3-
More informationヒト血漿中オキシステロールの高感度分析法
High sensitive determination of oxysterols in human plasma using gas chromatography-mass spectrometry (GC-MS) Saori Nakagawa and Susumu Yamato Oxysterols, cholesterol oxidation products, have been important
More informationVOL. 25 NO. 6 CHEMOTHERAPY 1667
1666 CHEMOTHERAPY AUG. 1977 VOL. 25 NO. 6 CHEMOTHERAPY 1667 1668 CHEMOTHERAPY AUG. 1977 VOL. 25 NO. 6 CHEMOTHERAPY 1669 VOL. 25 NO. 6 CHEMOTHERAPY 1671 1672 CHEMOTHERAPY AUG. 1977 VOL. 25 NO. 6 CHEMOTHERAPY
More informationCHEMOTHERAPY SEPT. 1992
VOL.40 S-4 CHEMOTHERAPY SEPT. 1992 Fig. 1. Plasma levels of cefclidin and ceftazidime in animals after a single intravenous administration (20mg/kg). Table 1. Pharmacokinetic parameters of cefclidn and
More information活用ガイド (ソフトウェア編)
(Windows 98 ) ii iii iv v NEC Corporation 1999 vi P A R T 1 P A R T 2 vii P A R T 3 viii P A R T 4 ix P A R T 5 x P A R T 1 2 3 1 1 2 4 1 2 3 4 5 1 1 2 3 4 5 6 6 7 7 1 1 2 8 1 9 1 1 2 3 4 5 6 1 2 3 10
More informationi
i ii iii iv v vi vii viii ix x xi ( ) 854.3 700.9 10 200 3,126.9 162.3 100.6 18.3 26.5 5.6/s ( ) ( ) 1949 8 12 () () ア イ ウ ) ) () () () () BC () () (
More information